如何优化心力衰竭患者的利尿剂的使用?
Michel Burnier1,2,3, Krzysztof Narkiewicz4, Sverre E Kjeldsen5
1Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland. michel.burnier@netplus.ch.
Kardiologia polska
|September 18, 2023
概括
在心力衰竭中优化利尿疗法至关重要. 本综述探讨了先进的策略,如顺序性脏阻塞和新药类,以改善患者的治疗结果和减少住院治疗.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 利尿药物治疗对于治疗心力衰竭至关重要,但液体过载往往被诊断不足,治疗的标位不够.
- 目前的治疗常常依赖于经典的利尿剂,而新的药物类提供了额外的治疗选择.
研究的目的:
- 审查和讨论心力衰竭管理的优化利尿剂策略.
- 探索目前可用的药物的使用,超越传统的利尿剂.
主要方法:
- 对心力衰竭利尿剂管理的药理学方法的审查.
- 对药物组合和新型治疗剂的讨论.
主要成果:
- 优化的利尿疗法可以涉及连续性脏阻塞.
- 结合疗法包括氨酸 - ангиотензин系统 (RAS) 阻断剂,尿素抑制剂 (ARNI),结合剂,矿物质皮质抗剂和SGLT2抑制剂.
- 这些策略旨在改善流体管理和患者的治疗结果.
结论:
- 战略性使用多种利尿剂和相关药物类别可以增强心力衰竭管理.
- 优化治疗预计将改善生活质量,并减少心力衰竭患者的住院和死亡率.
相关概念视频
Heart Failure Drugs: Diuretics
418
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
418
Heart Failure V: Medical Management
12
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
12
Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Antihypertensive Drugs: Action of Diuretics
811
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
811
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
460
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
460
Heart Failure Drugs: Inotropic Agents
617
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
617


